Halo joins Bayer's Phase III studies for MRI agent gadoquatrane

Menlo Park, CA-based Halo Precision Diagnostics has joined Bayer’s multinational phase III clinical development program, Quanti.

The collaboration will include three clinical trials that explore how contrast-enhanced MRI using gadoquatrane impacts the central nervous system; other body regions such as head and neck, thorax, abdomen, pelvis, and extremities; and whether it is effective and safe in children 18 and younger.

If successful, gadoquatrane, an investigational gadolinium-based contrast agent, will result in lower gadolinium doses for patients, Halo said.